UK Markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8900+0.2700 (+10.31%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.08
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 311.9500
52-week low 32.0000
50-day moving average 32.8653
200-day moving average 34.2209

Share statistics

Avg vol (3-month) 327.02k
Avg vol (10-day) 378.46k
Shares outstanding 579.31M
Implied shares outstanding 6N/A
Float 851.61M
% held by insiders 10.00%
% held by institutions 11.66%
Shares short (28 Apr 2022) 4127.11k
Short ratio (28 Apr 2022) 45.38
Short % of float (28 Apr 2022) 4N/A
Short % of shares outstanding (28 Apr 2022) 40.16%
Shares short (prior month 30 Mar 2022) 4134.74k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin -213.78%
Operating margin (ttm)-193.60%

Management effectiveness

Return on assets (ttm)-10.40%
Return on equity (ttm)-34.53%

Income statement

Revenue (ttm)24.7M
Revenue per share (ttm)0.31
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-22.3M
EBITDA -43.23M
Net income avi to common (ttm)-45.48M
Diluted EPS (ttm)-1.1070
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)119.84M
Total cash per share (mrq)1.51
Total debt (mrq)44.25M
Total debt/equity (mrq)41.19
Current ratio (mrq)1.73
Book value per share (mrq)1.69

Cash flow statement

Operating cash flow (ttm)-58.46M
Levered free cash flow (ttm)-15.02M